Nuowei Bio's First-in-Class Therapeutic DNA Vaccine NWRD08 Receives IND Approval for Cervical HSIL Caused by HPV16/18

Oct 31, 2023 10:12 CST Updated 10:12

Newish

Developer of Next-Generation Anti-Tumor DNA Vaccines

Recently, NEWISH's independently developed NWRD08 naked plasmid DNA injection (NWRD08) has officially received the implied permission for clinical trials from the National Medical Products Administration., Indications:Treatment of HSIL Patients with Cervical HPV16 and/or HPV18 Positivity。

NWRD08 is a product from NEWISH this year.The Second First-in-Class Nucleic Acid New Drug Approved for IND, used to eliminate HPV viruses and remove precancerous lesions. The company holds full independent intellectual property rights. In May this year, NEWISH's novel Class 1 drug NWRD06, a DNA nucleic acid vaccine for liver cancer, received IND approval and is currently undergoing Phase I clinical research in collaboration with the Hepatobiliary Surgery Department of the Cancer Hospital, Chinese Academy of Medical Sciences.

The IND-approved HPV therapeutic DNA nucleic acid vaccine, NWRD08, a Class 1 new drug, targets the oncogenes E6 and E7 of the HPV16/18 virus. Its core sequence adopts a targeted enhancement strategy linked to chemokines.A recombinant fusion plasmid DNA drug formed by linking a "unique" chemokine to the target antigen through a linker, administered via electroporation delivery, is a first-of-its-kind innovation in China and globally.。

About NEWISH

NEWISH Focuses on Early Cancer Treatment, Concentrating on the Development of Immunotherapy and First-in-Class Gene Therapy with Complete Independent Intellectual Property Rights. It Has Established a Core Technology Platform in Collaboration with Academician Jiang Jiandong: The STARi (Super Targeting Activated Response of Immunization, Super-Targeted Activation of T-Cell Immune Response) Nucleic Acid Drug Development Platform, Which Employs a Strategy of Enhancing T-Cell Immunity Through Chemokine-Conjugated Targeting to Develop Next-Generation Cancer Vaccines and Antiviral Drugs. NEWISH Aims to Address Unmet Clinical Needs and Is Committed to Becoming a Global Leader in the Development of New Drugs for Early Cancer Treatment.

E.N.D

In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。